Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity

Virology Journal

Volumn 9, Issue , 2012, Pages

  Zhao, Qinjian ^a,d   Modis, Yorgo ^b   High, Katrina ^a   Towne, Victoria ^a   Meng, Yuan ^a   Wang, Yang ^a,e   Alexandroff, Jaime ^a   Brown, Martha ^a   Carragher, Bridget ^c   Potter, Clinton S ^c   Abraham, Dicky ^a   Wohlpart, Dave ^a   Kosinski, Mike ^a   Washabaugh, Mike W ^a,f   Sitrin, Robert D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b YALE UNIVERSITY   (United States)

^c Nano Imaging Services   (United States)

^d XIAMEN UNIVERSITY   (China)

^e Sino Biological Inc   (China)

^f MEDIMMUNE   (United States)

Author keywords

Atomic homology model; Competitive fluorescence ELISA; Epitope mapping; Neutralizing monoclonal antibody; Recombinant subunit vaccine; Redox treatment; Virus like particle (VLP)

Indexed keywords

CAPSID PROTEIN L1; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN; VIRUS ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BOVINE PAPILLOMAVIRUS TYPE 1; CONTROLLED STUDY; CROSS REACTION; CRYOELECTRON MICROSCOPY; EPITOPE MAPPING; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR STABILITY; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN FOLDING; VIRION; VIRUS ASSEMBLY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PURIFICATION; WART VIRUS; ANTIBODY AFFINITY; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; IMMUNOLOGY; PAPILLOMA VIRUS; PROTEIN BINDING; PROTEIN CONFORMATION; ULTRASTRUCTURE;

BOVINE PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS; MIRIDAE;

ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CAPSID PROTEINS; EPITOPE MAPPING; EPITOPES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MODELS, MOLECULAR; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; PROTEIN BINDING; PROTEIN CONFORMATION; VIRION; VIRUS ASSEMBLY;

EID: 84862812041     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-52     Document Type: Article

References (50)

1. Virus-like particles in vaccine development. Roldao A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM, Expert Rev Vaccines 2010 9 1149 1176 10.1586/erv.10.115 20923267
2. HPV prophylactic vaccination: The first years and what to expect from now. Villa LL, Cancer Lett (N Y, NY, U S) 2011 305 106 112
3. Prevention of cancer by prophylactic human papillomavirus vaccines. Kwak K-H, Yemelyanova A, Roden RBS, Curr Opin Immunol 2011 23 244 251 10.1016/j.coi.2010.11.009 21185706
4. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Munoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, et al. J Eur Acad Dermatol Venereol 2009 23 1147 1155 10.1111/j.1468-3083.2009.03266.x 19453788
5. Developing an HPV vaccine to prevent cervical cancer and genital warts. Bryan JT, Vaccine 2007 25 3001 3006 10.1016/j.vaccine.2007.01.013 17289220 (Pubitemid 46482731)
6. Prevention of cancer through immunization: prospects and challenges for the 21st century. Frazer IH, Lowy DR, Schiller JT, Eur J Immunol 2007 37 148 S155 10.1002/eji.200737820 17972339 (Pubitemid 350131279)
7. Prevention and treatment of papillomavirus-related cancers through immunization. Frazer IH, Leggatt GR, Mattarollo SR, Annu Rev Immunol 2011 29 111 138 10.1146/annurev-immunol-031210-101308 21166538
8. Arrangement of L2 within the papillomavirus capsid. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL, J Virol 2008 82 5190 5197 10.1128/JVI.02726-07 18367526 (Pubitemid 351705228)
9. Process for making human papillomavirus virus-like particles with improved properties. Zhao Q, Wu S, Manger W, Gadam S, US Patent 6,436,402 2002
10. Maturation of papillomavirus capsids. Buck CB, Thompson CD, Pang Y-YS, Lowy DR, Schiller JT, J Virol 2005 79 2839 2846 10.1128/JVI.79.5.2839-2846.2005 15709003 (Pubitemid 40270562)
11. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA, J Virol 1998 72 32 41 9420197 (Pubitemid 28048810)
12. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi L, J Pharm Sci 2006 95 2195 2206 10.1002/jps.20696 16871523 (Pubitemid 44568530)
13. Polymorphism in the assembly of polyomavirus capsid protein VP1. Salunke D, Caspar DLD, Garcea RL, Biophys J 1989 56 887 900 10.1016/S0006-3495(89)82735- 3 2557933
14. Invariant polymorphism in virus capsid assembly. Nguyen H, Reddy VS, Brooks CL, J Am Chem Soc 2009 131 2606 2614 10.1021/ja807730x 19199626
15. Generalized structural polymorphism in self-assembled viral particles. Nguyen H, Brooks CL, Nano Lett 2008 8 4574 4581 10.1021/nl802828v 19367856
16. GARDASIL: Prophylactic human papillomavirus vaccine development-from bench top to bed-side. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, Kosinski M, Washabaugh MW, Sitrin R, Barr E, Clin Pharmacol Ther 2007 81 259 264 10.1038/sj.clpt.6100055 17259949 (Pubitemid 46174823)
17. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA, Virology 1996 223 174 184 10.1006/viro.1996.0466 8806551 (Pubitemid 26302057)
18. Hybrid Papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct hpv types. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU, Virology 2001 291 324 334 10.1006/viro.2001.1220 11878901 (Pubitemid 34095188)
19. Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples. Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R, et al. Hum Vaccines 2005 1 191 197 10.4161/hv.1.5.2126
20. Evaluation of the thermal stability of Gardasil. Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, et al. Hum Vaccines 2006 2 147 154 10.4161/hv.2.4.2989
21. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT, Clin Diagn Lab Immunol 2003 10 108 115 12522048 (Pubitemid 36133838)
22. Multiplexed serologic assay for nine anogenital human papillomavirus types. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT, Clin Vaccine Immunol 2010 17 818 827 10.1128/CVI.00348-09 20237197
23. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. Roden RBS, Armstrong A, Haderer P, Christensen ND, Hubbert NL, Lowy DR, Schiller JT, Kirnbauer R, J Virol 1997 71 6247 6252 9223527 (Pubitemid 27304974)
24. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA, J Virol 2003 77 11625 11632 10.1128/JVI.77.21. 11625-11632.2003 14557648 (Pubitemid 37271661)
25. Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes. Cason J, Patel D, Naylor J, Lunney D, Shepherd PS, Best JM, McCance DJ, J Gen Virol 1989 70 2973 2987 10.1099/0022-1317-70-11-2973 2479716 (Pubitemid 19283616)
26. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. Wang D, Christensen N, Schiller JT, Dillner J, J Gen Virol 1997 78 2209 2215 9292008 (Pubitemid 27387034)
27. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Culp TD, Spatz CM, Reed CA, Christensen ND, Virology 2007 361 435 446 10.1016/j.virol.2006.12.002 17222883 (Pubitemid 46574856)
28. Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. High K, Meng Y, Washabaugh MW, Zhao Q, Anal Biochem 2005 347 159 161 10.1016/j.ab.2005.09.007 16229811 (Pubitemid 41608581)
29. Solution antigenicity analysis of human papillomavirus type 16 virus-like particles preparations by antibody binding IC50 and affinity constant determination. Meng Y, High K, Wang Y, Washabaugh M, Zhao Q, Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States 2004 BIOL-229
30. Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Dillner J, Dillner L, Utter G, Eklund C, Rotola A, Costa S, DiLuca D, Int J Cancer 1990 45 529 535 10.1002/ijc.2910450326 1689705 (Pubitemid 20087204)
31. Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. Wang X, Wang Z, Christensen ND, Dillner J, Virology 2003 311 213 221 10.1016/S0042-6822(03)00179-X 12832218 (Pubitemid 36794224)
32. Crystal structures of four types of human Papillomavirus L1 Capsid Proteins: understanding the specificity of neutralizing monoclonal antibodies. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS, J Biol Chem 2007 282 31803 31811 10.1074/jbc.M706380200 17804402 (Pubitemid 350044858)
33. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME, J Immunol Methods 1985 77 305 319 10.1016/0022-1759(85)90044-4 3981007 (Pubitemid 15103678)
34. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS, Virology 1996 224 477 486 10.1006/viro.1996.0554 8874508 (Pubitemid 26364495)
35. In-depth process understanding of RECOMBIVAX HB((R)) maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Zhao Q, Towne V, Brown M, Wang Y, Abraham D, Oswald CB, Gimenez JA, Washabaugh MW, Kennedy R, Sitrin RD, Vaccine 2011 29 7936 7941 10.1016/j.vaccine.2011.08.070 21871939
36. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Zhao Q, Wang Y, Abraham D, Towne V, Kennedy R, Sitrin RD, Biochem Biophys Res Commun 2011 408 447 453 10.1016/j.bbrc.2011.04.048 21527246
37. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Zhao Q, Allen MJ, Wang Y, Wang B, Wang N, Shi L, Sitrin RD, Nanomedicine 2012 doi:10.1016/j.nano.2012.01. 007
38. Structural basis of oligosaccharide receptor recognition by human papillomavirus. Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, Spillmann D, Bishop B, Sapp M, Chen XS, J Biol Chem 2011 286 2617 2624 10.1074/jbc.M110.160184 21115492
39. Subunit interactions in bovine papillomavirus. Wolf M, Garcea RL, Grigorieff N, Harrison SC, Proc Natl Acad Sci USA 2010 107 6298 6303 10.1073/pnas.0914604107 20308582
40. Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. Zhao Q, Guo HH, Wang Y, Washabaugh MW, Sitrin RD, J Virol Methods 2005 127 133 140 10.1016/j.jviromet.2005.03.015 15894387 (Pubitemid 40828190)
41. Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. Sapp M, Fligge C, Petzak I, Harris JR, Streeck RE, J Virol 1998 72 6186 6189 9621087 (Pubitemid 28283413)
42. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT, Hum Vaccines FIELD Full Journal Title:Human Vaccines 2007 3 109 115 (Pubitemid 47501028)
43. Atomic model of the papillomavirus capsid. Modis Y, Trus BL, Harrison SC, EMBO J 2002 21 4754 4762 10.1093/emboj/cdf494 12234916
44. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, Waterboer T, Pawlita M, J Gen Virol 2008 89 117 129 10.1099/vir.0.83145-0 18089735
45. Finestructure epitope mapping of antierythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E, Giffin J, Hesterberg L, Blood 1996 87 2702 2713 8639886 (Pubitemid 26102219)
46. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. Park S, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, Wong W, Kerwin B, J Pharm Sci 2009 98 1688 1699 10.1002/jps.21546 18781649
47. Leatherbarrow R, GraFit (5) Data Fitting Software Horley Syrrey, UK: Erithacus Software limited 2006
48. Automated molecular microscopy: the new Leginon system. Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, Stagg S, Potter CS, Carragher B, J Struct Biol 2005 151 41 60 10.1016/j.jsb.2005.03.010 15890530 (Pubitemid 40848375)
49. Coot: model-building tools for molecular graphics. Emsley P, Cowtan K, Acta Crystallogr D: Biol Crystallogr 2004 60 2126 2132 10.1107/S0907444904019158 (Pubitemid 41742764)
50. Refinement of macromolecular structures by the maximum-likelihood method. Murshudov GN, Vagin AA, Dodson EJ, Acta Crystallogr D: Biol Crystallogr 1997 53 240 255 10.1107/S0907444996012255 (Pubitemid 27235885)